With this collaboration, Stallergenes Greer aims to strengthen its precision medicine-based approach and the management of patients with allergies by expanding its knowledge of allergy pathophysiology and endotypes, AIT mode of action and clinical validation.
This research collaboration brings together the longstanding expertise of Stallergenes Greer in AIT and Alyatec's competencies in research and clinical services as well as its technology, including a new generation environmental exposure chamber.
Allergies are the most prevalent and fastest growing chronic disease in the industrialised world, affecting over one bn people worldwide. Allergen immunotherapy is an allergy treatment designed to alter the natural course of respiratory allergies by treating the underlying cause of the disease.
Allergen extracts are modifying disease by inducing tolerance in the immune system.
Headquartered in London, Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services.
Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Alyatec is a contract research organisation based in Strasbourg University Hospital (France) which performs clinical studies related to respiratory allergies.
Thanks to its specific knowledge and medical expertise Alyatec can evaluate the effect of solutions against asthma, rhinitis and conjunctivitis caused by environmental factors such as cat allergens, pollens and house dust mites.
To perform these clinical trials, Alyatec has an environmental exposure chamber which enables the assessment of the mode of action of allergy treatment solutions in an innovative and efficient way.
The company provides a full range of clinical services in the area of respiratory allergies with all the benefits related to the use of Alyatec's allergen exposure unit.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary